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The Umbilical Cord
An Ally in Targeted Imaging Research?*
Jonathan R. Lindner, MD, Scott Chadderdon, MD
Portland, OregonThe emergence of methods for molecular imaging
with contrast-enhanced ultrasound reflects a gen-
eral broadening of the scope for all forms of medical
imaging. The goal of this trend is to evaluate
pathophysiology at the molecular level rather than
to image the structural or functional consequences
of disease. Most commonly this approach relies on
the detection of bioengineered targeted contrast
probes. There is an important role for molecular
imaging in both pre-clinical investigation and in
See page 997
patient care. In the clinical setting, imaging key
molecular mediators or markers of disease may
allow very early detection of disease or provide more
definitive information on the presence and extent of
disease. It may also provide a powerful tool for
rapidly testing new therapeutic strategies or to
select the most optimal therapy based on the active
molecular participants or disease phenotype, a form
of “individualized medicine.” An established exam-
ple where targeted probes have made a major
impact can be found in cancer medicine where
radionuclide imaging with 111In-labeled monoclo-
nal antibody against CD20 (ibritumomab) has been
used to detect and stage B-cell non-Hodgkin’s
lymphoma and to select patients who will benefit
from anti-CD20 radioimmunotherapy (1).
In cardiovascular medicine, molecular imaging
could potentially be used to improve risk assessment
in atherosclerotic disease, to increase sensitivity for
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the Division of Cardiovascular Medicine, Oregon Health & Science
University, Portland, Oregon.detecting thrombus, or to create new diagnostic
algorithms for detecting ischemia, myocarditis, or
transplant rejection. It is probably naïve to believe
that any one imaging method (radionuclide, cardiac
magnetic resonance, ultrasound, computed tomog-
raphy imaging) will be the best option for all of
these cardiovascular applications. As in the past,
imaging technologies will instead be matched to
clinical purpose and circumstance. The use of
contrast-enhanced ultrasound with targeted micro-
bubble agents will likely be considered when tem-
poral resolution, cost, and availability/portability are
important considerations and when the molecular
target of interest is amenable to a contrast agent
that is confined to the vascular compartment.
Potential uses for ultrasound and microbubbles
extend beyond diagnostics. There has been remark-
able progress in the field of ultrasound-mediated
gene transfer whereby the bioeffects produced by
microbubble cavitation in an ultrasound field can be
used to increase gene delivery and transfection (2).
This effect is enhanced when complementary de-
oxyribonucleic acid is directly coupled to the surface
of albumin or cationic lipid microbubbles (3,4). The
ability to focus ultrasound provides an avenue for
transfection to a specific tissue of interest. The exact
mechanism(s) responsible for enhanced transfection
with ultrasound destruction of microbubble vectors
is unknown. Some of the putative mechanisms
include transient cellular microporation from high-
pressure jets (microstreaming), ballistic effects, and
stimulation of endocytosis.
The paper by Barreiro et al. (5) in this issue of
iJACC describes a series of experiments in which:
1) targeted microbubbles were used to detect ex-
pression of intercellular adhesion molecule-1 and
CD9 in umbilical cord vessels; and 2) ultrasound-
mediated disruption of microbubbles was used to
amplify transfection of plasmid complementary de-
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1007xyribonucleic acid for a green fluorescent protein
eporter gene in an umbilical vessel with static flow.
revious work has already evaluated the in vitro
ell-binding kinetics of microbubbles targeted to
ndothelial cell adhesion molecules such as selec-
ins, intercellular adhesion molecule-1, vascular cell
dhesion molecule-1, v-integrins, among others
6–10). Molecular imaging with these agents has
een used to assess inflammatory phenotype in
therosclerotic disease, to detect recent myocardial
schemia and transplant rejection, and to evaluate
he molecular mediators of ischemia-mediated an-
iogenesis (6–10). This study introduces a new
odel to study microbubble behavior that may be
mportant for future probe development. The field
f drug discovery now has a well-established route
hereby individual candidate molecules that are
elected randomly through combinatorial chemistry
re screened with high-throughput robotic biosen-
or assays. The milestones for the development of
ovel ultrasound molecular imaging probes follow a
omewhat different route (Fig. 1). This process
egins with the creation of a single targeted probe
ith a specific diagnostic purpose in mind. Almost
ll of the progress in the field thus far has advanced
p to step 3, testing in pertinent animal models of
isease. The fourth step, engineering of probes
uitable for human testing, involves much more
han just a switch to an appropriate human target-
ng ligand. Targeted microbubble agents are multi-
alent particles. Accordingly, microbubble formula-
ions must be tested to evaluate the relative effects
f the myriad of factors that can affect binding such
s: 1) the binding kinetics for different ligands (or
ombination of ligands); 2) ligand surface density;
) length of molecular spacer arm that projects the
igand from the bubble surface; 4) presence of other
olymers (e.g., polyethylene glycol) on the bubble
urface; 5) target molecule density; 6) vascular shear
orce; and 7) pulsatility of flow, to name a few.
High-throughput methods with human tissues
re needed for the testing of human-ready micro-
ubble agents. Flow chamber studies with cultured
uman cells are not the answer because these
reparations do not necessarily recapitulate normal
r diseased human tissues and are influenced by
rocedural variables such as passage history and
ontact inhibition. The study by Barreiro et al. (5)
ntroduces the concept of using intact ex vivo
uman umbilical vessels to test targeted micro-
ubble contrast agents in the human vascular envi-
onment and to evaluate tissue distribution of
ltrasound-mediated gene transfer. With regard to ohe latter, adequate models are also needed to
ystematically test important variables of ultrasound-
ediated transfection (microbubble preparation,
coustic power, ultrasound frequency, pulsing inter-
al) and to optimize the balance between desired
nd detrimental bioeffects. Although umbilical ves-
els may not be satisfactory for modeling most
uman disease conditions, alternative sources of ex
ivo diseased vascular tissue, such as human carotid
rteries, have also been used to test binding of novel
robes (11).
Descriptive studies may provide particularly use-
ul information when they identify a mechanism or
enerate a hypothesis (12). The paper by Barreiro et
l. (5) reminds us that evolutions in methodology
lso play an important role for promoting progress
n a field.
cknowledgments
he authors thank Chad Carr, MD, and Stuart
unting, PhD, for their helpful comments and
houghts.
eprint requests and correspondence: Dr. Jonathan R.
indner, Cardiovascular Division UHN-62, Oregon
ealth & Science University, 3181 SW Sam Jackson
ark Road, Portland, Oregon 97239. E-mail: lindnerj@
Creation of a targeted probe with an established targeting l
In vitro testing of probe binding kinetics
In vivo application of probe in established animal model of d
Probe modification for human use
Safety testing in humans
Efficacy testing in humans
Figure 1. Development of Ultrasound Probes for Molecular Ima
Flow chart schematically representing the general process of pre-cl
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